Delving into the Latest Updates on YTS-109 with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms

YTS 109, YTS109

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesHemic and Lymphatic DiseasesOther Diseases

Active Indication

Autoimmune Haemolytic AnaemiasAutoimmune Diseases

Inactive Indication-

Originator Organization

BriSTAR Immunotech LimitedStartup

Active Organization

BriSTAR Immunotech LimitedStartup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 START T-cell therapy in patients with autoimmune hemolytic anemia who have failed ≥3 lines of therapy.

Start Date16 Jan 2025

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

[+1]

NCT06379646

/ RecruitingNot Applicable

An Exploratory Clinical Study of the Safety and Efficacy of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease

Start Date24 Apr 2024

Sponsor / Collaborator

BriSTAR Immunotech LimitedStartup

[+1]